|
|
 |
|
Total Number of Holdings (excluding cash): 49
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
61,392 |
$73,175,580.48 |
7.56% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
279,181 |
$68,083,870.47 |
7.03% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
523,220 |
$67,165,751.40 |
6.94% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
260,862 |
$67,036,316.76 |
6.92% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
1,038,998 |
$66,651,721.70 |
6.88% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,170,073 |
$35,350,489.17 |
3.65% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
168,801 |
$34,820,270.28 |
3.60% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
83,644 |
$33,863,273.40 |
3.50% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Drug Retailers |
141,556 |
$33,642,198.96 |
3.47% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
41,572 |
$32,098,156.92 |
3.31% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
65,332 |
$31,622,647.96 |
3.27% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
1,171,667 |
$30,697,675.40 |
3.17% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
217,317 |
$28,438,102.62 |
2.94% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
48,002 |
$25,582,185.88 |
2.64% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
98,019 |
$25,156,576.35 |
2.60% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
200,488 |
$23,733,769.44 |
2.45% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
107,406 |
$20,806,690.32 |
2.15% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
247,012 |
$19,086,617.24 |
1.97% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
62,370 |
$16,559,858.70 |
1.71% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
301,456 |
$15,736,003.20 |
1.63% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
25,252 |
$14,772,672.52 |
1.53% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
147,001 |
$12,606,805.76 |
1.30% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
77,215 |
$12,340,501.30 |
1.27% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
245,534 |
$11,876,479.58 |
1.23% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
185,140 |
$11,378,704.40 |
1.18% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
159,881 |
$11,327,568.85 |
1.17% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
103,464 |
$10,700,246.88 |
1.11% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
95,036 |
$10,366,526.88 |
1.07% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
149,495 |
$9,335,962.75 |
0.96% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
193,532 |
$8,825,059.20 |
0.91% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
320,273 |
$7,750,606.60 |
0.80% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
47,516 |
$7,487,571.28 |
0.77% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
148,010 |
$7,333,895.50 |
0.76% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
48,503 |
$7,090,168.54 |
0.73% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
380,663 |
$6,878,580.41 |
0.71% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
22,286 |
$6,688,920.04 |
0.69% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
76,716 |
$6,584,534.28 |
0.68% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
218,788 |
$6,198,264.04 |
0.64% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
153,947 |
$5,406,618.64 |
0.56% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
16,325 |
$5,267,914.25 |
0.54% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
48,992 |
$5,213,238.72 |
0.54% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
181,651 |
$5,167,970.95 |
0.53% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
48,497 |
$4,564,295.15 |
0.47% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
83,161 |
$4,479,051.46 |
0.46% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
165,323 |
$4,369,486.89 |
0.45% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
58,911 |
$3,848,655.63 |
0.40% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
81,194 |
$3,796,631.44 |
0.39% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
54,943 |
$2,993,844.07 |
0.31% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
13,366 |
$2,888,659.92 |
0.30% |
| US Dollar |
$USD |
|
Other |
1,489,726 |
$1,489,725.87 |
0.15% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|